Sector
PharmaceuticalsCMP
as on 01 Jul, 2024 12:00:00 AM
Open
₹3.49Prev. Close
₹3.49Turnover(Lac.)
₹0.01Day's High
₹3.49Day's Low
₹3.4952 Week's High
₹3.4952 Week's Low
₹2.31Book Value
₹1.03Face Value
₹10Mkt Cap (₹ Cr.)
6.67P/E
0EPS
0Divi. Yield
014 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
29 Aug 2023
12:00 AM
BookCloser
29 Aug 2023
12:00 AM
AGM
Announcement Date: 29 Aug, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 19.11 | 19.11 | 19.11 | 19.11 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -16.32 | -15.29 | -15.16 | -10.75 |
Net Worth | 2.79 | 3.82 | 3.95 | 8.36 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0 | 0 | 4.09 | 2.84 |
yoy growth (%) | -100 | -99.89 | 43.98 | 109.88 |
Raw materials | 0 | 0 | -3.52 | -8.23 |
As % of sales | 0 | 18.49 | 86.16 | 289.72 |
Employee costs | -0.4 | -0.45 | -0.65 | -0.79 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -4.49 | -1.23 | -1.05 | -7.44 |
Depreciation | -0.55 | -0.57 | -0.58 | -0.59 |
Tax paid | 0.07 | 0.06 | 0.19 | 0.05 |
Working capital | 0.77 | -1.49 | -0.12 | -10.03 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -100 | -99.89 | 43.98 | 109.88 |
Op profit growth | 512.82 | 28.2 | -92.35 | 1,295.21 |
EBIT growth | 263.47 | 17.16 | -85.82 | 567.87 |
Net profit growth | 278.49 | 34.81 | -88.28 | 520.78 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,528.5 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,565 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,482.85 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,095.1 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,500 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Peeyush Kumar Aggarwal
Company Sec. & Compli. Officer
Pooja Chuni
Independent Director
Madhu Sharma
Director
Ram Niwas Sharma
Additional Director
Ajay Sharma
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by MPS Pharmaa Ltd
Summary
MPS Pharmaa Limited (Formerly known Advik Laboratories Limited) was incorporated in September, 1994. The Company was promoted in by the Jains along with a group of dedicated professionals. Presently, it is engaged in the manufacture and sale of pharmaceutical products in India. It offers ethical, generic, and over the counter drugs in various formulations. The companys generic product portfolio comprises antibacterial; antiallergics; antifungals; analgesic, antipyretic, and anti-inflammatory; antihypertensives; anthelminthics; antimalarials; corticosteroids; erectile dysfunction; gastrointestinal agents; sedatives; and other miscellaneous products. The company commenced commercial production in 1997. In his leadership, the company has witnessed a fast growth rate, without compromise to quality.During the year 2003-2004, the company established their brand, Zin - Ten (an anti- allergic tablets) in the oversea market. During the year 2004-2005, the company launched the new marketing set up and necessary approvals were taken for the new range of product like Majispa, Robial, Chewfe-C, Stibomin, Wibatol, Wibatol-O, Twosum, and Arfagel. During the year 2007-2008, the company compliance of current guidelines requires good amount of funds for modernization of its plant as per standards of WHO-GMP level.In 2021-22, the Company became an Associate Company of Vikas Lifecare Limited as it had acquired 22.04% of the shareholding of the Company. As a result, on 20-06-2022, Vikas Lifecare
Read More
What is the MPS Pharmaa Ltd share price today?
The MPS Pharmaa Ltd shares price on nse is Rs.₹3.49 today.
What is the Market Cap of MPS Pharmaa Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of MPS Pharmaa Ltd is ₹6.67 Cr. as of 01 Jul ‘24
What is the PE and PB ratio of MPS Pharmaa Ltd?
The PE and PB ratios of MPS Pharmaa Ltd is 0 and 3.38 as of 01 Jul ‘24
What is the 52 Week High and Low of MPS Pharmaa Ltd?
The 52-week high/low is the highest and lowest price at which a MPS Pharmaa Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of MPS Pharmaa Ltd is ₹2.31 and ₹3.49 as of 01 Jul ‘24
What is the CAGR of MPS Pharmaa Ltd?
MPS Pharmaa Ltd's CAGR for 5 Years at 21.84%, 3 Years at 46.50%, 1 Year at 51.08%, 6 Month at 25.09%, 3 Month at 8.72% and 1 Month at 4.80%.
What is the shareholding pattern of MPS Pharmaa Ltd?
The shareholding pattern of MPS Pharmaa Ltd is as follows:
Promoters - 35.89 %
Institutions - 0.58 %
Public - 63.53 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
